Understanding Hemophilia A and B Drug Dosage Administration Patterns

Study Design

A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings.

30 sites will enroll approximately 300 patients

Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate.

Physicians complete a retrospective chart review on each enrolled patient.

Patients will complete a one-time study questionnaire.

• Hemophilia A
• Hemophilia B

• Drug: Hemophilia B standard half-life
  
  Benefix
• Drug: Hemophilia B extended half-life
  
  Alprolix
• Drug: Hemophilia A standard half-life
  
  Xyntha and other standard half-life agents
• Drug: Hemophilia A extended half-life
  
  Eloctate and Adynovate

• Hemophilia B
  
  real world administration patterns and resource utilization implications
  Interventions:
  

  • Drug: Hemophilia B standard half-life
  • Drug: Hemophilia B extended half-life
• Hemophilia A
  
  real world administration patterns and resource utilization implications
  Interventions:
  

  • Drug: Hemophilia A standard half-life
  • Drug: Hemophilia A extended half-life

Physician/Clinician Participants:

• Must be a healthcare provider
• Currently manages at least 10 hemophilia A and/or B patients

Patient Participants:

• Willing and able to provide informed consent
• Diagnosed with hemophilia A or B
• Current disease severity is either moderately severe or severe with a clotting factor level of ?5%
• If suffering from hemophilia A, must be currently taking moroctocog alfa (or another standard half-life treatment), rurioctocog alfa or efraloctocog alfa for at least six months.

(If currently taking rurioctocog alfa or efraloctocog alfa, must have been switched from a standard half-life treatment and had been on that prior treatment for at least six months).

• If suffering from hemophilia B, must be currently taking nonacog alfa or eftrenonacog alfa for at least six months (If currently taking eftrenonacog alfa, must have switched from nonacog alfa and had been on that prior treatment for at least six months).
• Infuse at least 3 times per month

Exclusion criteria:

• Female with hemophilia A or B
• Mild Haemophilia A or B